Amplia Therapeutics Ltd (ASX:ATX)’s John Lambert speaks with Proactive’s Ky Chow about how Amplia’s lead drug AMP945 is fighting back against cancer and lung diseases. Lambert talks to the efficacy of its investigational focal adhesion kinase (FAK) inhibitor, AMP945, and how it is comparable to the current market leader, OFEV®, used to idiopathic pulmonary fibrosis. The company CEO and MD states that clinical studies to date have shown that AMP945 has an excellent safety and tolerability profile at doses that result in measurable inhibition of idiopathic pulmonary fibrosis. This augers well for Amplia, given its favourable comparison to OFEV®, which in 2020 recorded net sales of EU$2.5 billion (AU$3.7 billion) and CHF$1.1 billion (AU$1.6 billion).
Amplia Therapeutics’ inhibitor AMP945 shows comparable efficacy to market leading treatment
